Effects of LGM on a Primate Model of Asthma
Award amount
$277,792Program and phase
STTR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Lignamed, LLC
- Proposal award date
- 2017-07-18
- Contract end date
- 2019-06-30
- UEI
- C8L8WEU3TE85
- Solicitation number
- PA16-303
- Topic code
- NIAID
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Optimization of LGM2605 for use as a device in lung transplant
- IND enabling development of LGM2605 as adjuvant treatment for asthma
- Optimization of LGM2605 for use as a device in lung transplant
- Graft-protective properties of LGM2605 in Lung Transplantation
- LGM2605 as a Mitigator of Space Radiation-Induced Vascular Damage
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
7 SBIR/STTR records share this UEI (2017–2020). Reported award amounts total $7,077,331. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Aeronautics and Space Administration